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4Abstract (238 words)
Aims: The hypothesis of “metabolically healthy obesity” implies that, in the absence of
metabolic dysfunction, individuals with excess adiposity are not at greater cardiovascular risk.
We tested this hypothesis in a large pan-European prospective study.
Methods and results: We conducted a case-cohort analysis in the 520,000-person European
Prospective Investigation into Cancer and Nutrition study (“EPIC-CVD”). During median
follow-up of 12.2 years, we recorded 7,637 incident coronary heart disease (CHD) cases. Using
cut-offs recommended by guidelines, we defined obesity and overweight using BMI, and
metabolic dysfunction (“unhealthy”) as ≥3 of elevated blood pressure, hypertriglyceridemia, low 
HDL-cholesterol, hyperglycemia, elevated waist circumference. We calculated hazard ratios
(HRs) and 95% confidence intervals (95% CI) within each country using Prentice-weighted Cox
proportional hazard regressions, accounting for age, sex, centre, education, smoking, diet and
physical activity. Compared to metabolically healthy normal weight people (reference), HRs
were 2.15 (95%CI: 1.79; 2.57) for unhealthy normal weight, 2.33 (1.97; 2.76) for unhealthy
overweight, and 2.54 (2.21; 2.92) for unhealthy obese people. Compared to the reference group,
HRs were 1.26 (1.14; 1.40) and 1.28 (1.03; 1.58) for metabolically healthy overweight and obese
people, respectively. These results were robust to various sensitivity analyses.
Conclusion: Irrespective of BMI, metabolically unhealthy individuals had higher CHD risk than
their healthy counterparts. Conversely, irrespective of metabolic health, overweight and obese
people had higher CHD risk than lean people. These findings challenge the concept of
“metabolically healthy obesity”, encouraging population-wide strategies to tackle obesity.
Keywords: Coronary Heart Disease; Adiposity; Obesity; Metabolic syndrome; Epidemiology
5Introduction
Overall and abdominal obesity, commonly measured by body mass index (BMI) and waist
circumference (WC), are important risk factors for coronary heart disease (CHD) (1-3). The
effects of obesity on CHD are thought to be largely mediated by other cardiometabolic risk
factors such as insulin resistance, atherogenic dyslipidemia, and type 2 diabetes (4). However,
many obese people have few or no elevated metabolic risk factors included in the definition of
the Metabolic Syndrome (MetS) (5), suggesting that there may be a group of obese people – the
“metabolically healthy obese” – who are not at higher cardiovascular risk (6). There is no
consensus on the criteria to define this subtype, and an estimated 3 to 57% of obese individuals
are considered “metabolically healthy obese” depending on the population under study and the
definition used (7). There has been conflicting evidence on whether metabolically healthy obese
people are at higher risk of cardiovascular disease (CVD) or type 2 diabetes (8-17), with recent
meta-analyses challenging the concept of the metabolically healthy obesity by showing higher
cardiovascular risk among obese individuals with no metabolic syndrome (14, 15, 17, 18). The
existence of “metabolically healthy obesity” has also been questioned by the latest European
Society of Cardiology (ESC) guidelines for CVD prevention (19). However, previous studies
have been limited by incomplete adjustment for potentially important confounders (such as
physical activity and smoking), short duration of follow-up (and hence small numbers of incident
CHD events) and use of composite outcomes, such as all-cause mortality. More powerful and
detailed studies with precisely defined outcomes are therefore needed to clarify the association
with CHD risk, since heterogeneous effects of obesity according to metabolic health could have
important implications for risk prevention strategies.
To address this, we analysed 7,637 incident CHD cases recorded during 12.2 years of follow-up
from the European Prospective Investigation into Cancer and Nutrition cardiovascular disease
(EPIC-CVD) case-cohort study. Our primary aim was to examine the separate and combined
associations of obesity and metabolic health with CHD.
6Methods
Study population
EPIC-CVD is a prospective case-cohort study nested within the European Prospective
Investigation into Cancer and Nutrition (EPIC) study. Briefly, EPIC includes 366,521 women
and 153,457 men, mostly aged 35 to 70 years old at baseline, recruited between 1991 and 1999
at 23 centres across 10 European countries: Denmark, France, Germany, Greece, Italy, the
Netherlands, Norway, Spain, Sweden, and the United Kingdom. Adults were invited from the
local general population except in the French centre (women in a national health insurance plan),
some Italian and Spanish centres (recruited through local blood donor associations), Utrecht (The
Netherlands) and Florence (Italy) (women invited for population-based breast cancer screening
programmes) and Oxford (UK) (specifically recruited a substantial proportion of vegetarians). At
baseline, participants gave a blood sample and completed questionnaires on diet, lifestyle, and
medical history. Detailed baseline characteristics of the EPIC cohort have been previously
described (20).
A case-cohort study nested in a large prospective cohort is similar to a nested case-control study
with the difference that a random subcohort is selected for use as a reference group, rather than
matched controls. This design is efficient as it does not require all study participants to have
exposure measurement and has the advantages of a longitudinal cohort study with prospective
assessment of key exposures that are not subject to recall bias. Unlike the nested case-control
design, it allows risk to be measured at any time until the end of follow-up and permits time-to-
event analysis (21). A representative random subcohort of 18,249 participants (62% women),
stratified by centre, was selected for the EPIC-CVD project, constituting a case-cohort design.
After exclusion of 609 participants with a prior history of myocardial infarction or stroke at
baseline, 17,640 subcohort members remained. In total in the EPIC study, 13,964 incident CHD
cases developed during follow-up, of whom 631 belong to the subcohort. Ethical review boards
of the International Agency for Research on Cancer and all local institutions where participants
had been recruited gave approval for the original EPIC study, and all participants gave written
informed consent.
Blood pressure measurements were not available for the centres in Norway, Asturias, or Navarra,
and WC was not recorded in Norway and Umea (22). These centres were excluded from the
analyses, as well as the French centre due to the limited number of incident CHD events (n=41).
Further exclusions were performed based on missing exposure and covariate data, described
7below. All analyses were performed in a sample restricted to participants with no missing data
(complete-case analysis). Because exclusions due to missing data may result in a selected
sample, we also used a multiple imputation approach as a sensitivity analysis to compare the
results with the complete-case approach. A schematic representation of the EPIC-CVD
case-cohort design and sample selection is given in Supplemental Figure 1.
Definitions of obesity and metabolic disorders
Trained health professionals measured blood pressure (BP) (23), weight, height, and waist
circumference (WC) (24), except in the France and Oxford centres where body size
measurements were self-reported (25). BMI was calculated as weight (kg) divided by the square
of height (m2). Obesity was defined according to the World Health Organization (26) as
BMI≥30 kg/m2, overweight as 25≤BMI<30 kg/m2, and normal weight as 18.5≤BMI<25 kg/m2.
Underweight (BMI<18.5) participants were excluded due to the limited number (n=264, less
than 1% of the subcohort).
Total cholesterol, HDL-cholesterol, triglycerides, and glucose were measured in baseline serum
samples on a Roche auto-analyser (Roche diagnostics, USA) and HbA1c was measured in the
erythrocyte fraction using the Tosoh-G8 HPLC analyser (Tosoh Bioscience, Japan) at Stichting
Huisartsen Laboratorium (Etten-Leur, Netherlands). Fasting status was available for 87% of
participants. Metabolic Syndrome (MetS) was defined according to the 2009 Joint Interim
Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for the Study of Obesity (5)
as having three or more of the following metabolic abnormalities: 1) elevated BP, defined as
systolic BP≥130 and/or diastolic BP≥85 mm Hg and/or use of antihypertensive medication at 
baseline and/or self-reported history of hypertension; 2) hypertriglyceridemia, defined as
triglycerides≥1.7mmol/L (150mg/dL) or current use of lipid-lowering medication at baseline; 3) 
low HDL-cholesterol, defined as <1.0mmol/L (40mg/dL) for men and <1.3mmol/L (50mg/dL)
for women; 4) hyperglycemia, defined as fasting blood glucose ≥5.6mmol/L (100mg/dL) or non-
fasting blood glucose≥7.8mmol/L (140mg/dL, with fasting defined as ≥3 hours between last 
meal and blood draw (27)), and/or current use of antidiabetic medication at baseline and/or self-
reported history of diabetes; or 5) elevated waist circumference, defined as WC≥94cm for men 
and WC≥80cm for women. Where information on fasting status was not available (23% of 
participants), the non-fasting cut-off was used for glucose. Diabetes was defined as a self-
reported history and/or HbA1c≥6.5%. 
8Covariate definition
Validated questionnaires were used to obtain information on education, smoking habits, dietary
intake (including alcohol intake), and physical activity at study baseline. The Cambridge Index
of physical activity was derived by combining occupational with recreational activity level to
produce four groups: active, moderately active, moderately inactive and inactive (28). Usual diet
over the previous 12 months was assessed using validated country/centre-specific dietary
questionnaires (24), allowing the calculation of food group, individual energy and nutrient
intakes (derived from the EPIC nutrient database (29)). To summarize diet quality for adjustment
purposes, we computed a Mediterranean diet score, ranging from 0-18, with greater scores given
to higher intakes of fruit, vegetables, legumes, nuts, grains, and fish, lower intakes of red meat
and dairy, and moderate intake of alcohol (30).
Outcome ascertainment
Incident CHD cases were defined as first CHD events, whether non-fatal or fatal, consisting of
ICD-10 codes I20-I25, which include myocardial infarction, other acute ischemic heart diseases,
chronic ischemic heart disease and angina pectoris (31). EPIC centres used methods including
self-report, linkage to primary and secondary care registers, hospital admissions and mortality
data to ascertain events. Non-fatal CHD events were further validated by additional review of
individual medical records and/or linkage with registries with validation rates ranging from 82%
to 100% (32), while fatal CHD events were generally ascertained through mortality registries.
End of follow-up for CHD events varied between centres and ranged between 2003 and 2010.
Participants known to have left the country were considered lost to follow-up and censored at
their date of last follow-up.
Statistical analyses
Characteristics of participants in the subcohort were described across body size phenotypes and
compared using ANCOVA, giving adjusted least square means and percentages (and confidence
interval) across the six phenotypes. Adjustments were made for centre, sex, age, education,
smoking status and energy intake (for description of dietary intake only).
To assess the association of adiposity markers and metabolically-defined body size phenotypes
with incident CHD, we used Prentice-weighted Cox proportional hazards models with robust
standard errors to account for the case-cohort design (21). Age was the underlying time scale,
with entry time defined as the participant’s age at recruitment and exit time as age at first fatal or
9non-fatal CHD event or censoring (whichever came first). For all analyses, we stratified the
models by sex and centre. To account for the multi-country design, we followed a 2-stage
approach where models were fitted separately within country and then country-specific HRs
were combined using multivariate random-effects meta-analysis (33).
To assess the shape of associations of BMI and WC with CHD risk, country-specific HRs were
calculated by comparing quintiles (defined using all participants) of baseline adiposity values
with the lowest quintile. The pooled hazard ratios were then plotted against mean values of the
adiposity measure within each quintile, accompanied by a group-specific confidence interval
derived only from the variance of the log risk in that category (including the reference quintile)
(34). As associations were approximately log-linear, we calculated HRs associated with 1
standard deviation (SD) higher baseline value (4.10 kg/m2 for BMI, 12.7 cm for WC).
Heterogeneity between countries was quantified using the I2 statistic (35).
For analyses of adiposity measures, Model 0 was adjusted for baseline age and smoking status
(never, former, current). Model 1 was further adjusted for highest educational level (no
schooling/primary, secondary, vocational/university), physical activity, Mediterranean diet score,
energy and alcohol intake. Model 2 was further adjusted for the different body size markers, i.e.
WC for BMI and BMI for WC. In Model 3, to explore biological pathways potentially
underlying the associations, we adjusted for baseline age, smoking status, and intermediate
cardiovascular risk factors: blood cholesterol (total and HDL), systolic blood pressure and
diabetes. Interactions on the multiplicative scale between BMI and WC and between BMI and
MetS were formally tested.
For analyses of metabolically-defined body size phenotypes, Model A was adjusted for baseline
age, smoking status (never, former, current) and highest educational level (no schooling/primary,
secondary, vocational/university). To investigate the potential mediating effect of lifestyle habits
(36, 37) on the association between metabolically-defined body size phenotypes and CHD risk,
we compared Model A to Model B, which further included adjustment for physical activity
(Cambridge index: inactive, moderately inactive, moderately active, active), alcohol
consumption (g ethanol/day), Mediterranean diet score and energy intake (kcal/day).
The primary complete-case analyses included only participants with non-missing data on
anthropometric measurements, blood pressure, blood biomarkers and all covariates, with
sensitivity analyses that maximised the number of participants by only excluding those with
missing data on the covariates in each analysis model. Additional sensitivity analyses performed
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were: 1) excluding the first 2 years of follow-up to minimise the potential for reverse causality;
2) including only “hard” CHD events, i.e. myocardial infarction and coronary death; 3) including
only events validated with a high level of certainty; 4) restricting analyses to “never smokers”
only, to apply more rigid control for smoking; 5) separately for men and women to investigate
potential differences by sex. For comparability with other studies, we also performed sensitivity
analyses with different definitions of obesity or metabolic health: 6) excluding the WC criterion
from the definition of MetS, modifying the definition of metabolically healthy to be <2
abnormalities (17, 38); 7) defining metabolically healthy participants as having none of four
possible abnormalities (elevated blood pressure, triglyceridemia, hyperglycemia, low HDL-
cholesterol); 8) using abdominal obesity index defined as WC≥102cm for men and WC≥88cm 
for women. For the latter, a model (Model C) was fitted including BMI as a continuous
covariate. Finally, 9) we used a multiple imputation approach to impute the missing values for
the non-systematically missing variables (i.e. after exclusion of the centres with no data on blood
pressure or waist circumference). Five imputed datasets were generated and estimates were
combined using Rubin’s rules.
All analyses were performed with SAS 9.3 (SAS Institute, Cary, NC) and STATA MP 13.1. We
summarize the key aspects of the modelling strategy in Supplemental Figure 2.
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Results
After exclusions, there were 10,474 subcohort participants and 7,637 incident CHD cases (394 of
whom are also in the subcohort) comprising a total of 17,733 participants who contributed
117,829 person-years at risk in the complete-case analysis. 63% of subcohort participants were
female and the mean (SD) age and BMI were 53.6 (9.3) years and 26.1 (4.1) kg/m2 respectively
(Table 1). Median follow-up was 12.2 years (interquartile range: 9.7 – 13.6). 15.8% of subcohort
participants were obese, 25.6% had MetS, whilst 45.2% of obese participants were
“metabolically healthy”. Metabolically healthy obese participants were younger and had lower
BMI than obese participants with MetS (p<0.0001). The metabolically healthy obese had worse
metabolic parameters (higher lipid levels, blood pressure, HbA1c, C-reactive protein), had higher
red meat intake, were less likely to be current smokers, more likely to be inactive and less
educated than metabolically healthy normal weight participants (all p<0.0001, Table 1). The
proportion of obese participants ranged from 11% in the UK to 30% in Greece and the
proportion of obese participants who were metabolically healthy ranged from 31.7% in Germany
to 57.9% in Spain (Supplemental Table 1).
Associations between body size and CHD
There was a positive approximately log linear association between BMI and CHD risk (Figure 1
and Table 2) after adjusting for potential confounders (Model 1): HR per-standard deviation =
1.25 (95% CI: 1.19, 1.32), p<0.0001. While the association was almost perfectly log-linear from
quintile 1 to 4, departure from log-linearity was observed at the highest quintile. The risk of
CHD almost doubled comparing the highest quintile (mean BMI = 32.7 kg/m2) to the lowest
quintile (mean BMI=21.5 kg/m2) (HR=1.96 [95% CI 1.66, 2.32], p<0.0001). The association was
substantially less strong after adjustment for WC (HR =1.06 [95% CI 0.97, 1.15], p=0.20), likely
reflecting the effect of lean mass and peripheral adipose tissue. The association was also
substantially attenuated in a model adjusted for intermediate cardiometabolic risk factors (blood
pressure, total and HDL-cholesterol, diabetes) (HR =1.05 [95% CI 1.01, 1.10], p=0.03, Table 2).
There was moderate heterogeneity across countries. Results were very similar in sensitivity
analyses that use all available individuals with complete data for each model in turn
(Supplemental Table 2). However, results with multiply imputed data showed that, despite
being strongly attenuated, the HRs remained significant when adjusted for WC or for
intermediate CVD risk factors (Supplemental Table 3). WC also had positive approximately
linear associations with CHD (Figure 1, Table 2), which were robust to adjustment for BMI
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(HR=1.24 [95% CI 1.10, 1.40], p<0.0001). Adjustment for cardiometabolic factors substantially
attenuated the association (Figure 1, Table 2).
There was a significant interaction between BMI and WC (p=0.005), with a weaker association
observed in the upper tertile of each anthropometric factor (Figure 2). For BMI, the HR per-
standard deviation increase was 1.27 (95% CI 1.17, 1.38) in the lowest tertile of WC, whereas it
was 1.10 (95% CI 1.03, 1.16) in the highest tertile. The association of WC with CHD was
stronger at every level of BMI than any of the associations of BMI with CHD across the tertiles
of WC: the HR per-standard deviation increase of WC was 1.65 (95% CI 1.43, 1.89) in the
lowest tertile of BMI and 1.29 (95% CI 1.21, 1.38) in the highest tertile of BMI.
Associations between metabolically-defined body size phenotypes and CHD
Compared to the normal weight participants without MetS (reference group), all other
metabolically-defined body size phenotypes were at significantly higher risk of CHD (Figure 3)
in a fully adjusted model (Model B). Metabolically healthy obese individuals were at higher risk
of CHD (HR=1.28 [95% CI 1.03, 1.58], p=0.02) but this was considerably lower than the risk in
metabolically unhealthy groups. MetS was strongly positively associated with CHD risk,
regardless of adiposity, with a HR of 2.15 (95% CI 1.79, 2.57: p<0.0001) for metabolically
unhealthy normal weight participants with MetS and a HR of 2.54 (95% CI 2.21, 2.92:
p<0.0001) in their obese counterparts. Results were generally consistent across countries
(Supplemental Figure 3; Figure 3). Similar results were obtained from models unadjusted for
physical activity and diet (Model A): the HRs were 1.25 (95% CI 1.14, 1.38) and 1.27 (95% CI
1.03 – 1.57) in the healthy overweight and obese, and 2.17 (95% CI 1.82, 2.59), 2.35 (95% CI
2.02, 2.74) and 2.63 (95% CI 2.30, 3.01) in the unhealthy normal weight, overweight and obese,
respectively. There were no significant interactions between BMI and MetS (p=0.19).
Sensitivity analyses show similar results after excluding the first 2 years of follow-up
(Supplemental Table 4), when analyses were restricted to “harder” CHD events only
(Supplemental Table 5), or when restricting the sample to non-smokers only (Supplemental
Table 6). Analyses restricted to events only validated to the highest level of certainty were
qualitatively similar but less precise (Supplemental Table 7). There was no difference between
men and women (p for interaction=0.63, Supplemental Table 8). Estimates from the multiple
imputation showed similar trends with the exception of an HR of greater magnitude for the
metabolically healthy obese (1.67 [95% CI 1.39; 1.99]) (Supplemental Table 3).
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Sensitivity analyses using a definition of MetS that excludes the WC criterion showed somewhat
stronger positive associations for all phenotypes (Supplemental Table 9). Results were
qualitatively similar to the main analysis (but less precise) when a stricter definition of
metabolically healthy was used (i.e. having none of the MetS abnormalities) (Supplemental
Table 10). Finally, when obesity was defined by WC (and not by BMI), and MetS did not
include the WC criteria, HRs were again qualitatively similar to the main analysis although
somewhat stronger (Supplemental Table 11). When further adjusted for BMI, HRs were
attenuated. Agreement between the two definitions of metabolically-defined body size
phenotypes where body size is defined by BMI or by WC was only moderate, with a weighted
kappa of 0.667 (Supplemental Table 12).
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Discussion
In this prospective case-cohort study with 7,637 CHD cases from 8 European countries
followed-up for a median of 12.2 years, we assessed the separate and combined effects of body
size and metabolic health on CHD. We observed higher CHD risk for general and central
adiposity, as defined by BMI and WC, respectively. Whilst the effect of BMI was substantially
attenuated on adjustment for WC, the effect of WC appeared to be robust to adjustment for BMI.
Metabolically healthy overweight and obese individuals were at higher risk of CHD compared to
their normal weight counterparts. However, CHD risk in metabolically unhealthy individuals
was markedly higher than in their metabolically healthy counterparts across all BMI categories.
Our study, which is the largest to address this question in terms of the number of incident CHD
events, suggests that “metabolically healthy” obesity is not a benign condition. This is of
particular importance as overweight people (BMI ≥25 and <30) with no traditional 
cardiometabolic risk factors are not recommended for weight loss treatment by recent UK or US
guidelines (39, 40). The risk of CHD in metabolically healthy overweight or obese individuals
was significantly lower than in the “metabolically unhealthy” groups, suggesting that obese and
overweight individuals without metabolic abnormalities are at intermediate cardiovascular risk
between metabolically healthy normal weight individuals and metabolically unhealthy
individuals. In support of this hypothesis, we showed that only 6% of the obese had strictly no
cardiometabolic abnormality vs 31% of the normal weight, and that metabolically healthy obese
individuals have worse cardiometabolic health than their normal weight counterparts, reflected
by higher blood pressure, HbA1c, pro-atherogenic lipids, and C-reactive protein. These data
concur with studies that used repeated measurements to evaluate the evolution of metabolically
healthy obesity over time, showing that metabolically healthy obese people were more likely to
go on to develop metabolic abnormalities (and become metabolically unhealthy obese) than their
normal weight counterparts (41-47). Despite being acknowledged as a risk factor for
cardiovascular disease, excess weight is not included in the prediction model SCORE (48). This
algorithm estimates the 10 year risk of fatal CVD and its use is recommended by the ESC
Guidelines for CVD risk assessment of patients to assist health professionals in their prevention
and treatment strategies (19). Our results suggest that, even in the absence of multiple traditional
CVD risk factors (smoking, type 2 diabetes, high blood pressure, high blood cholesterol),
weight-loss strategies through intensive lifestyle advice (diet, exercise and behaviour
modifications) or medical therapy (orlistat or bariatric surgery) should be recommended for
obese patients to try to achieve and maintain a healthy body weight to decrease CVD risk.
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Overall, these results support a population-wide strategy for prevention of obesity and
overweight regardless of the initial metabolic status of individuals.
In accordance with previous evidence on CVD, type 2 diabetes, breast and colorectal cancer (14,
17, 49-51), normal weight individuals with metabolic abnormalities had twice the risk of normal
weight individuals without metabolic abnormalities. This is consistent with the adverse effects of
metabolic factors in cardiovascular health, which are independent of obesity and accumulation of
fat, and could involve inflammation, high blood pressure, lipotoxicity and atherosclerosis (4, 52).
We also found that a higher WC was associated with higher risk of CHD at all levels of BMI,
including for those in the normal weight category. This is in line with pooled results from 11
prospective studies which found a linear positive association between WC and mortality risk at
all levels of BMI ranging from 20 to 50 kg/m2 (53), advocating for the importance of an
increased waistline at whole spectrum of BMI. Furthermore, a growing body of literature based
on novel imaging markers has shown heterogeneity in the cardiovascular phenotype of obesity
depending on location of adipose depots, with increased risk observed with visceral adipose
tissue compared to subcutaneous fat (54-56). This implies that targeted visceral fat loss, rather
than overall weight loss, may be a more efficient treatment of obesity to prevent cardiovascular
events. Medical therapy with orlistat, which leads to greater reduction in visceral adipose tissue
compared to placebo in clinical trials (57, 58), is a treatment option recommended by the latest
ESC guidelines (19).
Positive associations between BMI and WC and CHD are also consistent with previous evidence
(1-4). Our study confirms both the shape and magnitude of a combined analysis of 39
prospective studies (5,259 CHD cases) by the Emerging Risk Factors Collaboration (3), which
found a HR of 1.29 (1.22-1.37) for an increase in BMI of 4.56kg/m2 and 1.32 (1.24-1.40) for an
increase in WC of 12.6cm. Our results also align with those of the recent study by the Global
BMI Mortality Collaboration, which found a significantly higher risk of CHD death in both the
overweight and obesity groups compared with the normal weight group in an analysis including
3,599,426 participants and 54,872 CHD deaths (1). Although substantially attenuated, an
independent effect of BMI and WC remained after adjustment for major potential mediators
(SBP, cholesterol, diabetes), indicating that the excess risk for CHD due to high BMI or WC is at
least partially mediated by other factors. This is consistent with a pooled analysis of 97
prospective cohort studies from the Prospective Studies Collaboration (57,161 CHD cases),
which estimated that these three factors collectively explained 46% of the excess risk due to
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adiposity (4). The association between adiposity and CHD has been suggested to be causal by
Mendelian randomization studies, which have shown that genetic scores indexing BMI or waist-
to-hip ratio are associated with risk of CHD (59-61). Similar studies have shown causal
associations of adiposity with cardiovascular risk factors, supporting the hypothesis of mediation
by blood pressure and cholesterol (62).
Our study had various strengths, including its prospective design and its large sample size,
allowing assessment of risk in various subgroups. Anthropometric factors were mostly measured
by trained health professionals, which should reduce measurement error, and concomitant
measurement of weight, height and waist circumference allowed direct comparison of BMI and
WC in the same participants. The biomarkers measured and information on medical history
permitted exploration of various commonly used definitions of metabolic syndrome, and the
extensive information on covariates (smoking, physical activity, diet quality, alcohol, education)
allowed adjustment for a range of potential confounders. However, we cannot rule out the
possibility of unmeasured confounding. In particular, as behaviors like physical activity and diet
are self-reported at a single time point and were therefore prone to measurement error (28, 63), it
is likely that they were not fully captured.
Study limitations
A potential limitation when comparing our results with previous studies is the lack of
consistency in the definition of metabolically healthy obesity (38, 64). Moreover, by definition,
the MetS gives a simplified picture of diverse and complex phenotypes. To overcome this
limitation, we chose the most common definition (14, 15, 17) (absence of the MetS (5)), and
compared several alternative definitions in sensitivity analyses, all of which gave qualitatively
similar results. The absence of repeated assessment of metabolic health or adiposity during
follow-up meant we were unable to assess within-person variability in adiposity and shed light
on the proportion of metabolically healthy obese individuals who became metabolically
unhealthy, preventing analyses of “stable metabolically healthy obesity” and “transient
metabolically healthy obesity”. Finally, we acknowledge that some of the centres included in the
EPIC study are not representative of the general population, potentially limiting the
generalizability of our findings. For example, the prevalence of metabolically healthy obesity
within obese participants (45%) in EPIC-CVD is higher than in some other population-based
studies (64), suggesting that EPIC participants are likely to be healthier than the general
population. However, even if the participants are different from the general population, as long
17
as there is enough variability in the exposure (here, obesity and metabolic health markers), CHD
risk estimates and generalizability of the associations are unlikely to be affected.
Conclusions
In this large pan-European study, overweight and obesity were associated with higher risk of
CHD, even in the absence of metabolic syndrome. The presence of metabolic abnormalities was
associated with a higher risk of CHD at all levels of adiposity, including in normal weight
individuals. Overweight and obese individuals without metabolic dysfunction were at
intermediate risk of CHD between healthy normal weight and metabolically unhealthy
individuals. Our results highlight the importance of both obesity and metabolic health in CHD
prevention and do not support the concept of “metabolically healthy obesity”. Population-wide
prevention and treatment of obesity is therefore warranted, regardless of metabolic health.
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Figure Legends
Figure 1. Multivariate hazard ratios for coronary heart disease across quintiles of BMI (a,b,c) and waist
circumference (d,e,f)
Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI
estimated with robust variance, to take into account the case-cohort design. HRs were combined by multivariate
random-effects meta-analysis across 8 countries and accompanied by a group-specific confidence interval
(allowing a confidence interval to be attributed to the reference category). Age was used as the primary time
variable, and analyses were stratified by sex and centre. n=17,733 (7,637 cases)
Model 1 (a and d). Adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol
intake, educational level
Model 2. Model 1 + adjusted for WC (for BMI, b) or BMI (for WC, e)
Model 3 (c and f). Adjusted for age, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol,
history of diabetes
Abbreviations: BMI, body mass index; WC, waist circumference, CHD, coronary heart disease
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Figure 2. Multivariate hazard ratios (HRs, Model 1 a) for CHD associated with quintiles of BMI per sex-
specific tertile of WC (a,b,c) and quintiles of WC per sex-specific tertile of BMI (d,e,f)
a Country-specific HRs of CHD were estimated from Prentice-weighted Cox proportional hazards models, and
95%CI estimated with robust variance, to take into account the case-cohort design. HRs were combined by
multivariate random-effect meta-analysis across 8 countries and accompanied by a group-specific confidence
interval (allowing a confidence interval to be attributed to the reference category). Age was used as the primary
time variable, and analyses were stratified by sex and centre. n=17,733 (7,637 cases)
Model 1: Adjusted for age at baseline, smoking, physical activity, educational level, Mediterranean diet score,
energy and alcohol intake
HRs for quintiles of BMI, in the first (a), second (b) and third (c) sex-specific tertile of WC
Boundaries (cm) by tertiles: Tertile 1, 59-91(M), 54-76(F); Tertile 2, 92-99(M),77-86(F); Tertile 3, 100-151(M),
87-137(F) .
HRs for quintiles of WC, in the first (d), second (e) and third (f) sex-specific tertile of BMI
Boundaries (kg/m2) by tertiles: Tertile 1, 18.5-25.1(M), 18.5-23.8(F); Tertile 2, 25.1-27.9(M),23.8-27.4; Tertile
3, 27.9-49.4(M), 27.4-62.5(F).
P for interaction between BMI and WC = 0.005
Abbreviations: BMI, body mass index; WC, waist circumference; CHD, coronary heart disease
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Figure 3. Multivariate hazard ratios of CHD in metabolically-defined body size phenotypes.
a Country-specific HRs of CHD were estimated from Prentice-weighted Cox proportional hazards models, and
95%CI estimated with robust variance, to take into account the case-cohort design. HRs were combined by
multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time scale,
analyses were stratified by sex and centre, HRs adjusted for age, smoking, educational level, physical activity,
Mediterranean diet score, energy and alcohol intake (Model B). n=17,733 participants (7,637 CHD cases). P for
interaction between BMI and MetS = 0.19.
b Heterogeneity across 8 European countries
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Table 1. Baseline characteristics a of subcohort participants across metabolically defined body size phenotypes
Normal weight Overweight Obese
Metabolically
healthy normal
weight
Metabolically
unhealthy normal
weight
Metabolically
healthy overweight
Metabolically
unhealthy overweight
Metabolically
healthy obese
Metabolically
unhealthy obese
p Healthy
vs
unhealthy
obese b
p Healthy
obese vs
normal
weight b
Unadjusted
mean c
N 4282 368 2761 1403 751 909
Women (%) 69 (67, 71) 69 (64, 73) 55 (53, 57) 51 (48, 53) 64 (61, 67) 59 (56, 62) 0.01 0.01 63
Age (years) 50.8 (50.6, 51.1) 55.5 (54.7, 56.3) 52.3 (51.9, 52.6) 54.8 (54.4, 55.3) 52.8 (52.2, 53.4) 54.4 (53.9, 54.9) <.0001 <.0001 53.6 (9.3)
BMI (kg/m2) 22.7 (22.6, 22.7) 23.5 (23.3, 23.7) 26.9 (26.9, 27.0) 27.5 (27.4, 27.6) 32.6 (32.5, 32.8) 33.3 (33.2, 33.5) <.0001 NR 26.1 (4.1)
WC (cm)d 79.9 (79.7, 80.1) 85.5 (84.9, 86.2) 88.9 (88.7, 89.2) 93.1 (92.8, 93.5) 101.2 (100.8, 101.7) 105.2 (104.7, 105.6) NR NR 86.3 (12.6)
Glucose (mmol/l) d,e 4.78 (4.73, 4.83) 5.39 (5.24, 5.54) 4.80 (4.75, 4.86) 5.39 (5.31, 5.47) 4.83 (4.72, 4.93) 5.84 (5.74, 5.94) NR 0.40 5.04 (1.59)
HbA1c (%) 5.45 (5.43, 5.47) 5.62 (5.56, 5.68) 5.47 (5.45, 5.50) 5.69 (5.66, 5.72) 5.57 (5.52, 5.61) 5.96 (5.92, 6.00) <.0001 <.0001 5.5 (0.6)
SBP (mmHg) d 127.7 (127.1, 128.3) 137.6 (135.8, 139.3) 131.5 (130.8, 132.2) 139.0 (138.1, 139.9) 135.5 (134.2, 136.7) 143.2 (142.0, 144.3) NR <.0001 132.9 (19.7)
DBP (mm Hg) d 78.9 (78.5, 79.2) 84.0 (83.0, 85.0) 81.6 (81.2, 81.9) 85.5 (84.9, 86.0) 84.4 (83.7, 85.1) 87.9 (87.2, 88.6) NR <.0001 82 (10.7)
HDL, chol (mmol/l) d,e 1.60 (1.58, 1.61) 1.17 (1.13, 1.20) 1.48 (1.47, 1.50) 1.15 (1.13, 1.16) 1.46 (1.43, 1.48) 1.10 (1.08, 1.13) NR <.0001 1.48 (0.42)
Total chol (mmol/L) e 5.82 (5.78, 5.86) 6.35 (6.24, 6.46) 5.99 (5.95, 6.04) 6.33 (6.27, 6.39) 5.94 (5.87, 6.02) 6.23 (6.15, 6.30) <.0001 0.004 6.01 (1.13)
Non HDL, chol (mmol/l) e 4.22 (4.18, 4.26) 5.18 (5.07, 5.30) 4.51 (4.47, 4.55) 5.19 (5.13, 5.25) 4.49 (4.41, 4.57) 5.12 (5.05, 5.20) <.0001 <.0001 4.53 (1.18)
CRP (mg/L) 1.58 (1.43, 1.73) 2.06 (1.63, 2.49) 2.20 (2.03, 2.37) 2.63 (2.40, 2.86) 3.74 (3.44, 4.05) 4.39 (4.11, 4.67) 0.001 <.0001 2.34 (4.23)
Triglycerides (mmol/l) d, e 1.13 (1.10, 1.15) 2.25 (2.17, 2.33) 1.22 (1.19, 1.25) 2.25 (2.20, 2.29) 1.22 (1.16, 1.27) 2.31 (2.25, 2.36) NR 0.003 1.41 (0.93)
Vegetables (portions/d) f 2.67 (2.62, 2.71) 2.65 (2.52, 2.78) 2.68 (2.63, 2.73) 2.73 (2.66, 2.80) 2.60 (2.51, 2.70) 2.71 (2.62, 2.80) 0.08 0.19 2.54 (1.81)
Fruit (portions/d) g 2.92 (2.85, 2.99) 2.94 (2.73, 3.15) 3.09 (3.01, 3.17) 3.07 (2.96, 3.18) 3.03 (2.88, 3.18) 3.16 (3.03, 3.30) 0.17 0.19 3.02 (2.29)
Red meat (portions/d) h 1.03 (1.01, 1.05) 1.09 (1.03, 1.15) 1.12 (1.10, 1.14) 1.14 (1.11, 1.17) 1.15 (1.11, 1.19) 1.21 (1.17, 1.24) 0.05 <.0001 1.09 (0.74)
Mediterranean diet score 8.84 (8.77, 8.92) 8.64 (8.42, 8.86) 8.75 (8.66, 8.83) 8.76 (8.65, 8.88) 8.72 (8.57, 8.88) 8.59 (8.45, 8.74) 0.21 0.16 8.55 (3.08)
Energy intake (kcal/day) 2201 (2181, 2220) 2186 (2128, 2243) 2202 (2180, 2224) 2196 (2165, 2226) 2240 (2199, 2280) 2228 (2191, 2265) 0.67 0.08 2149 (623)
Alcohol (drinks/d) i 1.85 (1.78, 1.91) 1.82 (1.62, 2.01) 1.84 (1.76, 1.92) 1.82 (1.72, 1.93) 1.78 (1.64, 1.92) 1.72 (1.59, 1.85) 0.56 0.36 1.62 (2.13)
Physical activity (%)
Inactive 22 (21, 24) 25 (21, 29) 23 (22, 25) 27 (25, 29) 31 (28, 34) 32 (29, 34) 0.71 <.0001 23
Moderately inactive 34 (32, 35) 39 (35, 44) 34 (32, 36) 36 (33, 38) 29 (26, 33) 34 (31, 37) 0.04 0.02 33
Moderately active 24 (23, 25) 19 (14, 23) 22 (21, 24) 19 (17, 22) 20 (17, 23) 18 (16, 21) 0.37 0.02 22
Active 20 (19, 22) 16 (12, 21) 20 (19, 22) 17 (15, 20) 19 (17, 22) 16 (13, 19) 0.07 0.63 21
Education (%)
No schooling / Primary 35 (33, 36) 43 (39, 48) 43 (41, 44) 46 (44, 48) 52 (49, 55) 51 (48, 54) 0.65 <.0001 38
Secondary 15 (14, 16) 12 (09, 16) 14 (12, 15) 11 (09, 13) 11 (08, 13) 10 (07, 12) 0.44 0.002 15
Vocational/University 50 (48, 51) 44 (40, 49) 44 (42, 46) 43 (40, 45) 37 (34, 41) 40 (37, 43) 0.31 <.0001 47
Smoking status (%)
Never 42 (40, 44) 38 (33, 43) 45 (44, 47) 41 (38, 43) 46 (42, 49) 44 (41, 48) 0.54 0.04 45
Former 29 (27, 30) 24 (20, 29) 31 (29, 33) 33 (30, 35) 34 (31, 38) 32 (29, 35) 0.36 0.002 29
Current 30 (28, 31) 38 (34, 42) 24 (22, 25) 27 (24, 29) 20 (17, 23) 23 (20, 26) 0.10 <.0001 26
29
a Values are adjusted means or percentages (and confidence interval) from ANCOVA , adjusted for centre, sex, age, education, and smoking, as well as energy intake for
dietary variables.
b P-values were calculated using F-test
c Unadjusted means (SD) or percentages overall in the subcohort (n =10,474)
d Values in bold are components of the metabolic syndrome. The test for difference between metabolically healthy and unhealthy is not presented for these variables as it is
not relevant (NR).
e Conversion factors from mmol/L to mg/dL: glucose x18.02; cholesterol x38.67; triglycerides x88.57
f 1 vegetable portion = 80g
g 1 fruit portion = 80g
h 1 red meat portion = 110g of unprocessed meat and 50g of processed meat
i 1 alcoholic drink corresponds to 10g of ethanol
Abbreviations: BMI, body mass index; WC, waist circumference; chol, cholesterol; CRP, C-reactive protein; NR, not relevant
30
Table 2. Multivariate hazard ratios for coronary heart disease associated with body mass index and waist
circumference
HRa 95% CI p-value I2 b 95% CI
Model 0 c
BMI (kg/m2) 1.27 (1.21, 1.33) <.0001 44% (0%, 75%)
Waist circumference (cm) 1.34 (1.26, 1.42) <.0001 47% (0%, 76%)
Model 1 d
BMI (kg/m2) 1.25 (1.19, 1.32) <.0001 46% (0%, 76%)
Waist circumference (cm) 1.32 (1.24, 1.41) <.0001 51% (0%, 78%)
Model 2 e
BMI (kg/m2) 1.06 (0.97, 1.15) 0.20 19% (0%, 62%)
Waist circumference (cm) 1.24 (1.10, 1.40) <.0001 43% (0%, 75%)
Model 3 f
BMI (kg/m2) 1.05 (1.01, 1.10) 0.03 0% (0%, 68%)
Waist circumference (cm) 1.06 (1.00, 1.13) 0.06 34% (0%, 71%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI
estimated with robust variance, to take into account the case-cohort design. HRs were combined by multivariate
random-effects meta-analysis across 8 countries. HRs are expressed per 1 SD increase of anthropometric marker
(BMI: 4.10kg/m2, WC: 12.7cm), with age as the primary time variable, stratified by sex and centre. n=17,733
(7,637 cases)
b Heterogeneity across 8 European countries.
c Model 0. HR adjusted for age and smoking
d Model 1. HR adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol intake,
educational level
e Model 2. Model 1 + waist circumference (for BMI) or BMI (for waist circumference)
f Model 3. HR adjusted for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, history of
diabetes
Abbreviations: BMI, body mass index; CHD, coronary heart disease
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Table S1. Baseline characteristics a and metabolic health status in members of the subcohort, by country
Denmark Greece Germany Italy Netherlands Spain Sweden United Kingdom
N 1895 1124 1356 1800 1270 550 1481 998
Age (years) 56.6 (4.4) 52.2 (12.2) 50 (8.7) 50.3 (7.9) 52.7 (10.7) 50.6 (8.4) 57.6 (7.7) 57 (10.7)
Women (%) 46.7 61.7 60.5 66.3 83.9 68.0 61.7 60.6
MetS (%) 27.3 28.1 29.3 22.1 24.1 26.6 25.7 22.1
Normal weight (%) 43.8 27.9 45.6 45.7 51.8 23.3 51.7 51.5
Overweight (%) 42.6 42.0 39.3 39.4 36.4 46.9 37.0 37.5
Obese (%) 13.7 30.1 15.1 14.8 11.8 29.8 11.3 11.0
MHO (% of the obese) 38.6 55.0 31.7 46.8 48.7 57.9 37.1 40.9
a Values are unadjusted means (SD) or percentages.
n= 10,474 members of the subcohort included in the analytical sample
Abbreviations: MHO, metabolically healthy obese; MetS, metabolic syndrome
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S2. Sensitivity analysis: HR for CHD in different complete-case samples specific to each analysis.
HR a 95% CI p N cases N total I2 b 95% CI
BMI and Waist Circumference
Model 1 c
BMI 1.24 (1.17, 1.30) <.0001 9212 23634 55% (6%, 79%)
Waist circumference 1.31 (1.24, 1.38) <.0001 9212 23634 47% (0%, 76%)
Model 2 d
BMI 1.05 (0.97, 1.14) 0.23 9212 23634 33% (0%, 69%)
Waist circumference 1.24 (1.12, 1.37) <.0001 9212 23634 40% (0%, 73%)
Model 3 e
BMI 1.06 (1.01, 1.10) 0.01 8319 18700 6% (0%, 68%)
Waist circumference 1.07 (1.01, 1.14) 0.01 8319 18700 21% (0%, 63%)
Metabolically-defined body size phenotypes
Model B f
BMI MetS
Normal weight Metabolically Healthy 1.00 (ref) 2833 7664
Overweight Metabolically Healthy 1.26 (1.15, 1.38) <.0001 2513 6748 0% (0%, 68%)
Obese Metabolically Healthy 1.41 (1.15, 1.72) <.0001 687 2159 47% (0%, 77%)
Normal weight Metabolically Unhealthy 1.98 (1.67, 2.35) <.0001 530 929 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.26 (1.90, 2.67) <.0001 2172 3703 63% (19%, 83%)
Obese Metabolically Unhealthy 2.44 (2.11, 2.82) <.0001 1356 2495 4% (0%, 69%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effect meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre.
b Heterogeneity across 8 European countries.
c Model 1. HRs adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol intake, educational level
d Model 2. Model 1 + waist circumference (for BMI) or BMI (for waist circumference)
e Model 3. HRs adjusted for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, history of diabetes
f Model B. HRs adjusted for age, smoking, educational level, physical activity, Mediterranean diet score, energy and alcohol intake
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S3. Sensitivity analysis: HR for CHD where missing values are imputed by multiple imputation
HR a 95% CI p
BMI and Waist Circumference
Model 1 b
BMI 1.28 (1.24, 1.33) <.0001
Waist circumference 1.32 (1.27, 1.39) <.0001
Model 2 c
BMI 1.16 (1.07, 1.24) <.0001
Waist circumference 1.15 (1.05, 1.25) 0.002
Model 3 d
BMI 1.11 (1.06, 1.16) <.0001
Waist circumference 1.10 (1.04, 1.16) <.0001
Metabolically-defined body size phenotypes
Model B e
BMI MetS
Normal weight Metabolically Healthy 1.00 (ref)
Overweight Metabolically Healthy 1.35 (1.20, 1.52) <.0001
Obese Metabolically Healthy 1.67 (1.39, 1.99) <.0001
Normal weight Metabolically Unhealthy 1.78 (1.46, 2.18) <.0001
Overweight Metabolically Unhealthy 2.22 (1.98, 2.49) <.0001
Obese Metabolically Unhealthy 2.43 (2.09, 2.81) <.0001
a HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into account the case-
cohort design. Age was used as the underlying time scale, models were stratified by sex and centre. N=25,653 (12,240 cases). 5 imputed datasets, results
combined by Rubin’s rules.
b Model 1. HRs adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol intake, educational level
c Model 2. Model 1 + waist circumference (for BMI) or BMI (for waist circumference)
d Model 3. HRs adjusted for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, history of diabetes
e Model B. HRs adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol intake, educational level
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S4. Sensitivity analysis: HR for CHD after exclusion of first two years of follow-up across metabolically-defined body size phenotypes
BMI MetS HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal weight Metabolically Healthy 1.00 (ref) 1802 5961
Overweight Metabolically Healthy 1.22 (1.10, 1.35) <.0001 1581 4241 0% (0%, 68%)
Obese Metabolically Healthy 1.24 (0.99, 1.57) 0.07 323 1059 37% (0%, 72%)
Normal weight Metabolically Unhealthy 2.12 (1.74, 2.58) <.0001 428 778 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.30 (1.96, 2.72) <.0001 1678 2946 50% (0%, 78%)
Obese Metabolically Unhealthy 2.54 (2.23, 2.91) <.0001 976 1829 0% (0%, 68%)
Model B d
Normal weight Metabolically Healthy 1.00 (ref) 1802 5961
Overweight Metabolically Healthy 1.23 (1.11, 1.37) <.0001 1581 4241 0% (0%, 68%)
Obese Metabolically Healthy 1.25 (0.99, 1.58) 0.06 323 1059 35% (0%, 71%)
Normal weight Metabolically Unhealthy 2.09 (1.72, 2.54) <.0001 428 778 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.29 (1.90, 2.75) <.0001 1678 2946 58% (7%, 81%)
Obese Metabolically Unhealthy 2.46 (2.14, 2.82) <.0001 976 1829 0% (0%, 68%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying
time scale, models were stratified by sex and centre. n=16,814 (6,788 CHD cases).
b Heterogeneity across 8 European countries
c Model A. HRs adjusted for age, smoking, educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S5. Sensitivity analysis: HR for hard CHD (myocardial infarction) across metabolically-defined body size phenotypes
BMI MetS HR a 95%CI p-value N cases N total I2 b 95% CI
Model Ac
Normal weight Metabolically Healthy 1.00 (ref) 1303 6165
Overweight Metabolically Healthy 1.23 (1.07, 1.41) 0.003 1144 4451 0% (0%, 68%)
Obese Metabolically Healthy 1.32 (1.01, 1.73) 0.045 234 1103 43% (0%, 75%)
Normal weight Metabolically Unhealthy 2.13 (1.70, 2.67) <.0001 325 842 12% (0%, 71%)
Overweight Metabolically Unhealthy 2.21 (1.92, 2.55) <.0001 1283 3200 19% (0%, 62%)
Obese Metabolically Unhealthy 2.57 (2.17, 3.04) <.0001 773 1972 12% (0%, 72%)
Model B d
Normal weight Metabolically Healthy 1.00 (ref) 1303 6165
Overweight Metabolically Healthy 1.24 (1.08, 1.43) 0.002 1144 4451 3% (0%, 69%)
Obese Metabolically Healthy 1.30 (1.00, 1.70) 0.049 234 1103 39% (0%, 73%)
Normal weight Metabolically Unhealthy 2.10 (1.71, 2.58) <.0001 325 842 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.21 (1.89, 2.57) <.0001 1283 3200 26% (0%, 67%)
Obese Metabolically Unhealthy 2.46 (2.10, 2.90) <.0001 773 1972 1% (0%, 68%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre. n=17,733 participants (5,062 CHD cases)
b Heterogeneity across 8 European countries
c Model A. HRs adjusted for age, smoking, educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S6. Sensitivity analysis: HR for CHD events across metabolically-defined body size phenotypes in non-smokers only
BMI MetS HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal weight Metabolically Healthy 1.00 (ref) 1193 4166
Overweight Metabolically Healthy 1.22 (1.04, 1.38) 0.003 1173 3215 0% (0%,68%)
Obese Metabolically Healthy 1.26 (0.96, 1.67) 0.10 272 871 45% (0%,76%)
Normal weight Metabolically Unhealthy 2.15 (1.72, 2.69) <.0001 277 506 0% (0%,68%)
Overweight Metabolically Unhealthy 2.32 (2.00, 2.70) <.0001 1233 2193 7% (0%,70%)
Obese Metabolically Unhealthy 2.59 (2.21, 3.03) <.0001 763 1443 0% (0%,68%)
Model Bd
Normal weight Metabolically Healthy 1.00 (ref) 1193 4166
Overweight Metabolically Healthy 1.23 (1.08,1.40) 0.002 1173 3215 47% (0%, 80%)
Obese Metabolically Healthy 1.29 (0.99,1.67) 0.06 272 871 0% (0%, 79%)
Normal weight Metabolically Unhealthy 2.15 (1.71,2.71) <.0001 277 506 35% (0%, 75%)
Overweight Metabolically Unhealthy 2.32 (1.97,2.73) <.0001 1233 2193 44% (0%, 80%)
Obese Metabolically Unhealthy 2.58 (2.18,3.04) <.0001 763 1443 0% (0%, 79%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre. n=12,394 (4,911 cases)
b Heterogeneity across 8 European countries
c Model A. HRs age, smoking (never, former), educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S7. Sensitivity analysis: HR for CHD events with the highest level of certainty across metabolically-defined body size phenotypes
BMI MetS HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal weight Metabolically Healthy 1.00 (ref) 268 3159
Overweight Metabolically Healthy 1.39 (1.04, 1.86) 0.03 325 2598 40% (0%, 78%)
Obese Metabolically Healthy 1.11 (0.79, 1.55) 0.55 65 738 0% (0%, 79%)
Normal weight Metabolically Unhealthy 2.58 (1.68, 3.95) <.0001 75 374 21% (0%, 66%)
Overweight Metabolically Unhealthy 2.78 (2.17, 3.57) <.0001 389 1707 3% (0%, 80%)
Obese Metabolically Unhealthy 2.99 (2.36, 3.79) <.0001 262 1218 0% (0%, 79%)
Model Bd
Normal weight Metabolically Healthy 1.00 (ref) 268 3159
Overweight Metabolically Healthy 1.44 (1.05, 1.99) 0.03 325 2598 47% (0%, 80%)
Obese Metabolically Healthy 1.13 (0.81, 1.59) 0.47 65 738 0% (0%, 79%)
Normal weight Metabolically Unhealthy 2.79 (1.73, 4.49) <.0001 75 374 35% (0%, 75%)
Overweight Metabolically Unhealthy 2.88 (2.09, 3.98) <.0001 389 1707 44% (0%, 80%)
Obese Metabolically Unhealthy 2.93 (2.29, 3.77) <.0001 262 1218 0% (0%, 79%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre. n=9,794 (1,384 cases)
b Heterogeneity across 8 European countries
c Model A. HRs adjusted for age, smoking, educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis
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Table S8. Sensitivity analysis: HR for CHD across metabolically-defined body size phenotypes separately for men and women
BMI MetS HR a 95%CI p-value N cases N total I2 b 95% CI
Men
Normal weight Metabolically Healthy 1.00 (ref) 1053 2310
Overweight Metabolically Healthy 1.32 (1.16, 1.51) <.0001 1168 2328 0% (0%,68%)
Obese Metabolically Healthy 1.28 (0.99, 1.65) 0.06 184 415 7% (0%,70%)
Normal weight Metabolically Unhealthy 2.53 (1.90, 3.37) <.0001 243 346 45% (0%,76%)
Overweight Metabolically Unhealthy 2.35 (2.03, 2.73) <.0001 1239 1861 25% (0%,66%)
Obese Metabolically Unhealthy 2.47 (2.06, 2.95) <.0001 622 954 0% (0%,68%)
Women
Normal weight Metabolically Healthy 1.00 (ref) 925 3855
Overweight Metabolically Healthy 1.19 (1.03, 1.38) 0.02 609 2123 0% (0%,68%)
Obese Metabolically Healthy 1.28 (1.02, 1.60) 0.03 176 688 0% (0%,68%)
Normal weight Metabolically Unhealthy 1.85 (1.48, 2.31) <.0001 248 496 0% (0%,68%)
Overweight Metabolically Unhealthy 2.36 (2.01, 2.76) <.0001 677 1339 26% (0%,67%)
Obese Metabolically Unhealthy 2.72 (2.27, 3.26) <.0001 493 1018 30% (0%,69%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre. n=8,214 men (4,509 cases) and n=9,519 (n=3,128 cases).
HRs adjusted for age, smoking (never, former), educational level, physical activity, Mediterranean diet score, energy and alcohol intake
b Heterogeneity across 8 European countries
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Table S9. Sensitivity analysis: HR for CHD in metabolically-defined body size phenotypes where the definition of MetS does not include the waist
circumference criterion
BMI MetS without WC HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal weight Metabolically Healthy 1.00 (ref) 1458 5166
Overweight Metabolically Healthy 1.36 (1.20, 1.56) <.0001 1532 3999 6% (0%, 69%)
Obese Metabolically Healthy 1.43 (1.13, 1.81) 0.003 357 1095 42% (0%, 74%)
Normal weight Metabolically Unhealthy 2.01 (1.72, 2.35) <.0001 1011 1841 19% (0%, 62%)
Overweight Metabolically Unhealthy 2.52 (2.17, 2.94) <.0001 2161 3652 41% (0%, 74%)
Obese Metabolically Unhealthy 2.92 (2.54, 3.34) <.0001 1118 1980 0% (0%, 68%)
Model B d
Normal weight Metabolically Healthy 1.00 (ref) 1458 5166
Overweight Metabolically Healthy 1.38 (1.20, 1.57) <.0001 1532 3999 7% (0%, 70%)
Obese Metabolically Healthy 1.43 (1.14, 1.81) 0.002 357 1095 39% (0%, 73%)
Normal weight Metabolically Unhealthy 2.00 (1.72, 2.32) <.0001 1011 1841 8% (0%, 70%)
Overweight Metabolically Unhealthy 2.49 (2.11, 2.94) <.0001 2161 3652 48% (0%, 77%)
Obese Metabolically Unhealthy 2.82 (2.45, 3.25) <.0001 1118 1980 0% (0%, 68%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effect meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and centre. n=17,733 participants (7,637 CHD cases)
b Heterogeneity across 8 European countries
c Model A. HRs adjusted for age, smoking, educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
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Table S10. Sensitivity analysis: HR for CHD in metabolically-defined body size phenotypes where “metabolically healthy” is defined as having
none of the 4 abnormalities
BMI Healthy defined as having 0
abnormality
HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal weight Metabolically Healthy 1.00 (ref) 390 2148
Overweight Metabolically Healthy 1.24 (0.99, 1.56) 0.06 260 1040 0% (0%, 68%)
Obese Metabolically Healthy 1.15 (0.72, 1.84) 0.55 36 198 0% (0%, 68%)
Normal weight Metabolically Unhealthy 1.93 (1.62, 2.31) <.0001 2079 4859 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.67 (2.29, 3.12) <.0001 3433 6611 0% (0%, 68%)
Obese Metabolically Unhealthy 3.19 (2.64, 3.85) <.0001 1439 2877 0% (0%, 68%)
Model B d
Normal weight Metabolically healthy 1.00 (ref) 390 2148
Overweight Metabolically Healthy 1.24 (0.99, 1.56) 0.06 260 1040 0% (0%, 68%)
Obese Metabolically Healthy 1.21 (0.76, 1.92) 0.43 36 198 0% (0%, 68%)
Normal weight Metabolically Unhealthy 1.94 (1.62, 2.32) <.0001 2079 4859 0% (0%, 68%)
Overweight Metabolically Unhealthy 2.68 (2.28, 3.14) <.0001 3433 6611 0% (0%, 68%)
Obese Metabolically Unhealthy 3.12 (2.57, 3.80) <.0001 1439 2877 2% (0%, 68%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying
time scale, models were stratified by sex and centre. n=17,733 participants (7,637 CHD cases)
b Heterogeneity across 8 European countries
c Model A. HRs adjusted for age, smoking, educational level.
d Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
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Table S11. Sensitivity analysis: HR for CHD in metabolically-defined body size phenotypes where obesity is defined by WC, and MetS does not
include criteria on WC
WC MetS without WC HR a 95%CI p-value N cases N total I2 b 95% CI
Model A c
Normal WC d Metabolically Healthy 1.00 (ref) 1653 5707
Overweight e Metabolically Healthy 1.40 (1.15, 1.69) 0.001 1031 2729 55% (0%, 80%)
Obese f Metabolically Healthy 1.37 (1.11, 1.69) 0.003 663 1824 50% (0%, 78%)
Normal WC d Metabolically Unhealthy 1.96 (1.70, 2.25) <.0001 1143 2075 0% (0%, 68%)
Overweight e Metabolically Unhealthy 2.43 (2.09, 2.82) <.0001 1340 2292 20% (0%, 62%)
Obese f Metabolically Unhealthy 2.92 (2.47, 3.45) <.0001 1807 3106 47% (0%, 76%)
Model B g
Normal WC d Metabolically Healthy 1.00 (ref) 1653 5707
Overweight e Metabolically Healthy 1.41 (1.17, 1.70) <.0001 1031 2729 53% (0%, 79%)
Obese f Metabolically Healthy 1.39 (1.12, 1.73) 0.003 663 1824 51% (0%, 78%)
Normal WC d Metabolically Unhealthy 1.94 (1.68, 2.24) <.0001 1143 2075 0% (0%, 68%)
Overweight e Metabolically Unhealthy 2.43 (2.09, 2.84) <.0001 1340 2292 24% (0%, 65%)
Obese f Metabolically Unhealthy 2.84 (2.38, 3.39) <.0001 1807 3106 50% (0%, 77%)
Model C h
Normal WC d Metabolically Healthy 1.00 (ref) 1653 5707
Overweight e Metabolically Healthy 1.33 (1.10, 1.60) <.0001 1031 2729 44% (0%, 75%)
Obese f Metabolically Healthy 1.22 (0.99, 1.51) 0.06 663 1824 25% (0%, 66%)
Normal WC d Metabolically Unhealthy 1.93 (1.66, 2.24) <.0001 1143 2075 0% (0%, 68%)
Overweight e Metabolically Unhealthy 2.26 (1.92, 2.66) <.0001 1340 2292 21% (0%, 63%)
Obese f Metabolically Unhealthy 2.44 (1.99, 2.99) <.0001 1807 3106 25% (0%, 66%)
a Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI estimated with robust variance, to take into
account the case-cohort design. HRs were combined by multivariate random-effect meta-analysis across 8 countries. Age was used as the underlying time
scale, models were stratified by sex and EPIC study centre. n=17,733 participants (7,637 CHD cases); b Heterogeneity across 8 countries;
c Model A. HRs adjusted for age, smoking, educational level.;
d Normal WC: WC<94 for men, 80 for women; e Overweight: 94≤WC<102 for men, 80≤WC<88 for women; f Obese: WC≥102 for men, 88 for women 
g Model B included the same variables as model A + physical activity, Mediterranean diet score, energy and alcohol intake
h Model C included the same variables as model B + BMI
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Table S12. Cross-classification in metabolically-defined body size phenotypes where body size is defined by BMI or by WC
BMI-
defined
WC-defined
MHANW MUANW MHAOW MUAOW MHAO MUAO Total
MHNW 4447 999 648 0 71 0 6165
MUNW 0 394 0 391 0 57 842
MHOW 1246 452 1905 0 848 0 4451
MUOW 0 218 0 1753 0 1229 3200
MHO 14 8 176 0 905 0 1103
MUO 0 4 0 148 0 1820 1972
Total 5707 2075 2729 2292 1824 3106 17733
Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHOW, metabolically healthy
overweight; MUOW, metabolically unhealthy overweight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; MHANW,
metabolically healthy abdominally normal weight; MUANW, metabolically unhealthy abdominally normal weight; MHAOW, metabolically healthy
abdominally overweight; MUAOW, metabolically unhealthy abdominally overweight; MHAO, metabolically healthy abdominally obese; MUAO,
metabolically unhealthy abdominally obese.
Weighted kappa (95%CI), measuring agreement between two classifications, was 0.667 (0.660- 0.674)
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Figure S1. Schematic representation of the EPIC-CVD case-cohort design and sample included
in the complete-case analysis
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Figure S2. Schematic representation of the analysis strategy
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Figure S3. Country-specific HRs across metabolically-defined body size phenotypes compared
to metabolically healthy normal weight, Model B a
a Model B was adjusted for age, smoking, educational level, physical activity, Mediterranean diet
score, energy and alcohol intake



